Can I Take Ginseng with Leqvio (Inclisiran)?

What Inclisiran Actually Is and How It Works

Inclisiran is a small interfering RNA (siRNA) therapy approved by the FDA in December 2021 under the brand name Leqvio [1]. It targets PCSK9 messenger RNA inside hepatocytes, reducing the synthesis of PCSK9 protein and thereby increasing LDL receptor recycling on the liver cell surface. The net result is a sustained reduction in circulating LDL-C lasting roughly six months per dose.

A Different Pharmacokinetic Profile Than Most Drugs

Because inclisiran works via RNA interference rather than classical enzyme inhibition or receptor antagonism, its pharmacokinetic profile differs sharply from statins or fibrates [2]. The drug is delivered subcutaneously, taken up rapidly by hepatocytes via conjugated GalNAc ligands, and cleared from plasma within 24 to 48 hours of injection. Systemic plasma concentrations are therefore very low for most of the dosing interval.

Critically, inclisiran is not a substrate, inhibitor, or inducer of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 [1]. It is not transported by P-glycoprotein or OATP1B1/1B3 in a clinically meaningful way. This means the classical drug-herb pharmacokinetic interaction pathway that governs, for example, St. John's Wort or grapefruit interactions simply does not apply here.

ORION Trial Program: What the LDL-C Numbers Look Like

In the pooled ORION-9, ORION-10, and ORION-11 trials (combined N = 3,660 patients), inclisiran 284 mg produced a 49.9% mean time-averaged reduction in LDL-C from baseline versus placebo over 510 days (P<0.0001) [3]. Injection-site reactions were the most common adverse event, occurring in approximately 2.6% of inclisiran patients versus 0.9% on placebo. No hepatotoxicity signal emerged.

What Ginseng Is and Why It Raises Interaction Questions

"Ginseng" is not a single compound. The term covers several distinct species: Panax ginseng (Asian or Korean ginseng), Panax quinquefolius (American ginseng), and Eleutherococcus senticosus (Siberian ginseng, botanically distinct). Most pharmacological research centers on the ginsenoside fraction of Panax species [4].

Ginsenosides and CYP Enzymes

In vitro studies show that certain ginsenosides, particularly Rg1, Rb1, and compound K, can inhibit CYP3A4 and CYP2C9 at high concentrations [4]. However, these effects are typically seen at concentrations far above those achieved with standard supplement doses (100 to 400 mg standardized extract daily). Because inclisiran is not a CYP substrate at all, even the theoretical CYP inhibitory activity of ginsenosides carries no practical relevance to inclisiran therapy.

Glucose-Lowering Activity

American ginseng (Panax quinquefolius) has the most consistent evidence for modest glucose reduction. A randomized crossover trial by Vuksan et al. Published in the Archives of Internal Medicine found that 3 g of American ginseng taken 40 minutes before a 25 g oral glucose challenge reduced postprandial glucose area under the curve by approximately 20% in both diabetic and non-diabetic adults [5]. This effect is relevant because many patients taking inclisiran for ASCVD or familial hypercholesterolemia also have type 2 diabetes or prediabetes, and adding ginseng to an existing antidiabetic regimen could increase the risk of hypoglycemia.

Anticoagulant and Antiplatelet Activity

Several ginsenosides inhibit platelet aggregation in vitro by reducing thromboxane A2 synthesis and suppressing arachidonic acid pathways [6]. A prospective pharmacodynamic study found that Panax ginseng at 2 g daily significantly reduced platelet aggregation compared with placebo in healthy volunteers [6]. Inclisiran itself has no anticoagulant activity, so this concern is indirect: if a patient is also prescribed aspirin, clopidogrel, or warfarin alongside Leqvio for their cardiovascular disease (a common scenario), ginseng's antiplatelet action may potentiate bleeding risk.

Is There a Direct Interaction Between Ginseng and Inclisiran?

No published clinical trial has specifically studied co-administration of ginseng and inclisiran [1][3]. The interaction database maintained by the Natural Medicines Comprehensive Database classifies the ginseng-inclisiran combination as having insufficient evidence for a definitive rating, reflecting the absence of dedicated interaction studies rather than confirmed safety.

Why Pharmacokinetic Interaction Is Very Unlikely

The mechanism of inclisiran absorption and action insulates it from most herb-drug pharmacokinetic interactions:

• Inclisiran is delivered subcutaneously and does not undergo significant first-pass hepatic metabolism [2].
• Its plasma half-life is roughly 9 hours, and by 48 hours post-injection it is largely undetectable in plasma [1].
• Hepatic intracellular activity persists for months, but this intracellular RISC-loading phase is not subject to competitive CYP enzyme displacement.

Ginseng has no known mechanism to interfere with GalNAc receptor-mediated hepatocyte uptake or RISC complex formation.

Where Pharmacodynamic Overlap Could Occur

The table below maps the pharmacodynamic domains where ginseng and inclisiran's clinical context overlap:

| Domain | Inclisiran Effect | Ginseng Effect | Net Clinical Concern | |---|---|---|---| | LDL-C | 49.9% reduction [3] | Modest reduction (~5-10% in small trials) | Additive benefit, not a risk | | Blood glucose | Neutral | Lowers postprandial glucose [5] | Hypoglycemia risk if on antidiabetics | | Platelet function | None | Inhibits aggregation [6] | Bleeding risk if on anticoagulants | | Blood pressure | Neutral | May modestly lower BP [7] | Hypotension risk if on antihypertensives | | Hepatotoxicity | No signal in ORION trials [3] | Rare case reports of hepatotoxicity [8] | Monitor LFTs if both used long-term |

Who Faces the Most Risk: Patient Profiles That Warrant Extra Caution

Most patients taking inclisiran for heterozygous familial hypercholesterolemia or clinical ASCVD carry a cluster of comorbidities and co-medications. Ginseng's pharmacodynamic effects are not dangerous in isolation, but they can compound existing drug burdens.

Patients on Warfarin or Direct Oral Anticoagulants

Atrial fibrillation affects roughly 2 to 3% of the general population and a disproportionately higher fraction of ASCVD patients [9]. Warfarin-managed patients who add ginseng may see modest INR shifts. A randomized crossover study by Janetzky and Morreale found that Panax ginseng reduced warfarin's anticoagulant effect in one patient case series, while other data suggest potentiation [10]. The direction of effect is inconsistent, which itself argues for INR monitoring within two to four weeks of starting or stopping ginseng.

Patients with Type 2 Diabetes on Insulin or Sulfonylureas

The ACC/AHA 2019 guideline on the primary prevention of cardiovascular disease notes that patients with diabetes and established ASCVD should receive high-intensity statin therapy, and many will also be on injectable insulin or sulfonylureas [11]. Adding ginseng to this regimen may lower fasting glucose by 1 to 2 mmol/L in some studies [5], creating hypoglycemia risk. Self-monitoring of blood glucose for two to four weeks after starting ginseng is a reasonable precaution.

Patients on Multiple Antihypertensives

Hypertension coexists with ASCVD in a majority of inclisiran candidates. A meta-analysis of nine randomized controlled trials (N = 641) found that Panax ginseng reduced systolic blood pressure by a mean of 1.99 mmHg (95% CI: 0.09 to 3.88) [7]. For patients already at their blood pressure target on two or three agents, even this small additional effect could produce symptomatic hypotension, particularly in elderly patients.

What the Prescribing Information and Guidelines Say

The FDA-approved prescribing information for Leqvio (inclisiran) does not list ginseng or any botanical supplement as a contraindication or noted interaction [1]. No dose adjustment section addresses herbal co-administration.

The 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction recommends that clinicians ask about all supplements at each visit, given the broad cardiovascular polypharmacy typical of ASCVD patients [12]. The document states: "Patients should be specifically asked about over-the-counter medications, vitamins, and herbal or dietary supplements, as these may have cardiovascular or metabolic effects that interact with prescribed therapies." [12]

The American Heart Association's scientific statement on dietary supplements and cardiovascular disease notes that few herbal products have been rigorously evaluated in the context of modern lipid-lowering therapies, and that "the absence of a known interaction is not equivalent to confirmed safety." [13]

How Inclisiran Compares to Statins for Interaction Risk with Ginseng

Statins are CYP3A4 substrates (atorvastatin, simvastatin, lovastatin) or CYP2C9 substrates (rosuvastatin, fluvastatin). Because ginsenosides inhibit CYP3A4 in vitro at higher concentrations [4], the theoretical interaction risk with statins is actually higher than with inclisiran. Patients who tolerated ginseng on prior statin therapy should not assume the same risk profile applies to inclisiran co-prescription, because the patient population on inclisiran typically has more advanced cardiovascular disease and more co-medications.

Comparing siRNA Drugs for Supplement Interaction Risk

Inclisiran belongs to a new class. Its siRNA mechanism places it in a different interaction category than small-molecule PCSK9 inhibitors like evolocumab (Repatha) or alirocumab (Praluent), both of which are monoclonal antibodies cleared by lysosomal proteolysis rather than CYP enzymes [2]. None of these three agents appear to carry meaningful pharmacokinetic interaction risk with ginseng. The pharmacodynamic concerns outlined above apply equally across the PCSK9-lowering drug class.

Practical Monitoring Protocol if You Are Already Taking Both

If you are currently taking ginseng and your cardiologist or internist initiates inclisiran, the following monitoring steps are grounded in the pharmacodynamic interaction risks identified above:

At Baseline (Before the First Injection)

• Disclose the ginseng product name, dose, and frequency to your prescriber.
• Record your current fasting glucose or HbA1c if you have diabetes or prediabetes.
• Document your current INR if you are on warfarin.
• Note your standing blood pressure on your current antihypertensive regimen.

Within Four Weeks of the First Injection

• Recheck fasting glucose if diabetic, especially if taking sulfonylureas or insulin.
• Recheck INR if on warfarin. Aim for a recheck at two weeks and again at four weeks.
• Report any unusual bruising, bleeding gums, or prolonged bleeding from minor cuts.

At the Three-Month Injection Visit

• A standard lipid panel is recommended per ORION follow-up protocols [3]. Ask your provider to also check a fasting glucose and a comprehensive metabolic panel if you have liver disease risk factors.
• Reassess ginseng use. If LDL-C has reached target, your provider may discuss whether continuing ginseng offers any incremental benefit worth the monitoring burden.

Does Ginseng Add Any LDL-C Benefit on Top of Inclisiran?

The evidence for ginseng as a lipid-lowering agent is weak compared with inclisiran's established 49.9% LDL-C reduction [3]. A systematic review and meta-analysis of 26 randomized trials (N = 1,679) found that red ginseng reduced total cholesterol by a mean of 10.4 mg/dL and LDL-C by approximately 8.5 mg/dL compared with placebo [14]. These are clinically modest reductions. Patients already on inclisiran will have substantially lower LDL-C, and the marginal benefit of ginseng is unlikely to justify any added monitoring complexity for most people.

Patients seeking to further reduce residual LDL-C beyond what inclisiran achieves should discuss evidence-based options: adding ezetimibe (which reduced LDL-C by a further 23% when combined with a PCSK9 inhibitor in the FOURIER trial [15]), bempedoic acid, or optimizing statin dosing if tolerated.

What to Tell Your Doctor

The single most useful thing you can do is bring your ginseng supplement bottle to your next appointment. Your prescriber needs to see the standardized extract percentage, the ginsenoside content per capsule, and the brand, because "ginseng" on a label covers a wide potency range. Products standardized to 4 to 7% ginsenosides at doses above 400 mg daily carry more pharmacodynamic signal than low-potency products at 100 mg daily.

Specific questions worth asking:

1. Do you see any reason I should stop ginseng before my first Leqvio injection?
2. Should I recheck my INR or glucose sooner than my next scheduled visit?
3. Are there supplement alternatives with a better evidence base for my specific cardiovascular risk profile?